01 / CHARACTERIZATION
Capsid-content and vector analysis
Resolve empty, partial, and full capsids with a method matched to your decision window, from rapid screening to high-resolution confirmation.
AAV Capsid Content Resource
How Many AAV Particles Contain a Complete Genome? A Guide to Full, Empty, and Partially Filled Capsid Analysis
A high titer does not mean every particle is functional. Any AAV preparation is a mixture of full capsids that carry the complete genome, empty capsids that carry no DNA, and partially filled capsids that package truncated or incorrect sequences. AAV capsid-content analysis determines the proportion of full capsids carrying complete genomes versus empty, partially filled, or overfilled capsids. This distinction is essential because total titer alone may overestimate the functional dose and obscure product consistency. Methods such as AUC, SEC-MALS, and TEM help measure empty/full ratios, identify incomplete particles, and provide a more accurate assessment of AAV quality and potency.
01 Which capsid species are present? Full, empty, partial, and overfilled particles coexist in one sample.
02 Why can they be separated? Packaging shifts particle mass, density, and sedimentation.
03 Which method is the reference? AUC resolves empty, partial, and full capsids simultaneously.
04 Why does it matter? High empty-capsid fractions cut the effective dose and add unwanted immunogenicity.
Direct Answer
An AAV sample is never a single species
An AAV particle has two parts: the protein capsid and the vector genome inside it. Depending on whether, and how completely, the genome was packaged, particles fall into distinct populations—full, empty, partial, and occasionally overfilled. These populations coexist in every production run.
Because titer is typically reported as total genome copies per milliliter, it can overstate the biologically active dose when a large fraction of capsids are empty or partially filled. Quantifying the empty/full ratio therefore closes the gap between "how much virus is there" and "how much of it can actually deliver a transgene."
The key principle: total particle or genome titer is not potency. Pair titer with purity and capsid-content data to know the true functional dose.
Full Capsid
Complete genome
The capsid contains the intact vector genome and is the particle that most directly reflects therapeutic activity and dose.
Empty Capsid
No packaged DNA
A naked capsid with no genome contributes protein burden and immunogenicity but no transgene delivery, reducing the true effective dose.
Partial Capsid
Truncated or incorrect DNA
Partially filled capsids carry incomplete, truncated, or mispackaged fragments, lowering the fraction of the dose that is genuinely functional.
Overfilled Capsid
Excess packaged DNA
Overfilled particles package more than one genome or extra DNA, which can distort both identity and potency readouts if left unresolved.
Method Comparison
How empty, full, and partial capsids are measured
Empty and full capsids differ in mass, buoyant density, sedimentation behavior, and optical properties. Each analytical method exploits a different one of these differences, so the methods differ in resolution, throughput, and sample requirements.
| Method | Principle | What it resolves | Best role |
|---|---|---|---|
| AUC | Analytical ultracentrifugation separates particles by sedimentation and density | Empty, partial, and full capsids in one run | Reference-standard capsid-content analysis and release |
| SEC-MALS | Size-exclusion chromatography coupled to multi-angle light scattering | Mass-based separation of empty and full populations | High-resolution, orthogonal confirmation |
| TEM | Transmission electron microscopy visualizes stained particles | Direct visual distinction of empty vs. full by electron density | Imaging confirmation and aggregate assessment |
| Density gradient | Iodixanol or CsCl gradient centrifugation by buoyant density | Separates empty and full capsids into bands | Preparative separation, harder to scale quantitatively |
AUC is widely regarded as the reference method because it distinguishes empty, partial, and full capsids simultaneously. Creative Biolabs applies these tools within a broader high-resolution AAV capsid characterization program.
Why It Matters
What a high empty-capsid fraction costs you
Empty and partially filled capsids are not merely inert—they actively change the economics, safety, and interpretability of a dose.
-
01
Lower Effective Dose
A high total particle count with a low full fraction means fewer particles actually deliver the transgene.
-
02
Added Immunogenicity
Empty capsids still expose capsid protein, adding antigenic load and increasing the risk of an immune response.
-
03
Distorted Dosing
Dosing by total particles or genome copies can misstate the true functional dose when empties dominate.
-
04
QC Blind Spot
Titer alone cannot distinguish a potent batch from an empty-rich one, so potency data is required.
Quality Control
The quality metrics that accompany the empty/full ratio
The empty/full ratio is one of several quality attributes that together define a trustworthy AAV batch. Reading them as a set, rather than in isolation, gives the clearest picture of potency and safety.
Vector Genome Titer
Accurate genome copy number is the foundation that capsid-content data is normalized against.
Capsid Titer & Empty/Full Ratio
The fraction of full versus empty and partial capsids reveals how much of the sample is genuinely deliverable.
Genome Integrity
Confirming the packaged genome is intact rules out truncation as a hidden driver of low activity.
Residual Impurities
Host-cell DNA and protein, endotoxin, and aggregation all affect safety and reproducibility.
Batch Consistency
Track the empty/full ratio across runs to detect process drift before it compromises a campaign.
Fit-for-Purpose Panels
Research grade can combine titer, purity, and function; IND and GMP production add AUC or SEC-MALS.
Decision Framework
Choosing the right level of capsid analysis
The depth of empty/full analysis should match the stage of the program. Research-grade material and IND-enabling batches demand different levels of resolution.
Research-grade screening
Use: titer, purity, capsid/VG ratio, and functional readout for routine characterization.
Goal: confirm the vector works without over-engineering QC.
High-resolution characterization
Use: AUC or SEC-MALS when empty versus full distinction must be quantitative and defensible.
Goal: a robust empty/full ratio for process decisions and comparability.
IND and GMP release
Use: AUC or SEC-MALS plus the full panel of identity, purity, potency, and safety.
Goal: comprehensive capsid characterization that satisfies regulatory expectations.
Batch comparability
Use: trending the empty/full ratio across batches to catch process drift early.
Goal: consistent product quality across the whole campaign.
Analysis Outputs
From capsid data to a confident dose
Each capsid-content readout maps to a defined product-quality decision.
Full-capsid fraction
The deliverable portion of the dose.
Empty-capsid burden
Protein and immunogenicity load.
Process consistency
Ratio trending across batches.
Regulatory readiness
AUC/SEC-MALS backed characterization.
From Question to Evidence
Creative Biolabs Support
Creative Biolabs can integrate capsid-content analysis into your AAV program, connecting characterization, titration, purity, and production in a single decision-ready workflow.
02 / CAPSID QC
High-resolution capsid characterization
Apply AUC or SEC-MALS for a quantitative empty/full ratio that supports process decisions and regulatory release.
03 / TITRATION
Genome copy and infectious titer
Pair capsid-content data with genome and infectious titer to distinguish particle abundance from functional activity.
04 / PURITY
Purity and impurity assessment
Quantify empty-capsid burden and residual impurities that affect safety, dosing, and the interpretation of study results.
05 / PRODUCTION
Production and process support
Translate capsid-content insight into production decisions, reducing empty capsids at the source rather than only measuring them downstream.
Selected Reading
Scientific and regulatory context
Capsid Content
Wagner C, et al. Quantification of Empty, Partially Filled and Full Adeno-Associated Virus Vectors Using Mass Photometry. International Journal of Molecular Sciences. 2023;24(13):11033. https://doi.org/10.3390/ijms241311033.
Analytical Methods
Burnham B, et al. Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral Vectors. Human Gene Therapy Methods. 2015;26(6):228–242. https://doi.org/10.1089/hgtb.2015.048.
Comparative Study
Townsend J, et al. Comparative analysis of empty and full adeno-associated viruses under stress conditions by AEX, AUC, and mass photometry. Journal of Pharmaceutical Sciences. 2025. https://doi.org/10.1016/j.xphs.2025.01.005.
FAQ
AAV capsid content questions
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
